NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

HURA

TuHURA Biosciences Inc

Apr 28 • 04:00PM ET

3.97

Dollar change -0.13
Percentage change -3.17	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-75.32	Insider Own	43.50%	Shs Outstand	42.32M	Perf Week	-5.48%
Market Cap	173.41M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.00%	Shs Float	24.68M	Perf Month	9.67%
Income	-16.70M	PEG	-	EPS next Q	-0.13	Inst Own	5.03%	Short Float	7.77%	Perf Quarter	-5.02%
Sales	0.00M	P/S	-	EPS this Y	95.54%	Inst Trans	265.22%	Short Ratio	8.34	Perf Half Y	-22.00%
Book/sh	0.34	P/B	11.74	EPS next Y	-3.00%	ROA	-129.96%	Short Interest	1.92M	Perf Year	-17.39%
Cash/sh	0.43	P/C	9.30	EPS next 5Y	61.48%	ROE	-203.07%	52W Range	1.80 - 14.60	Perf YTD	-2.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	76.02%	ROI	-114.13%	52W High	-72.80%	Beta	0.49
Dividend TTM	-	Quick Ratio	3.68	Sales past 5Y	0.00%	Gross Margin	-	52W Low	120.56%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	3.68	EPS Y/Y TTM	64.00%	Oper. Margin	-	RSI (14)	54.49	Volatility	7.77% 11.38%
Employees	19	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.08
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	98.29%	Payout	-	Rel Volume	0.46	Prev Close	4.10
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 01 BMO	Avg Volume	229.99K	Price	3.97
SMA20	2.86%	SMA50	21.81%	SMA200	-23.88%	Trades		Volume	105,439	Change	-3.17%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-03-25	Initiated	H.C. Wainwright	Buy	$13
Dec-19-24	Initiated	Rodman & Renshaw	Buy	$11
Nov-05-24	Initiated	Maxim Group	Buy	$15

Apr-28-25 08:00AM	TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting (PR Newswire)
Apr-18-25 03:26PM	Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? (Insider Monkey)
Apr-08-25 08:00AM	TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting (PR Newswire)
Apr-07-25 08:24AM	TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management (PR Newswire) +7.69%
Apr-01-25 08:00AM	TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update (PR Newswire) -9.91%
08:05AM	Loading…
Mar-11-25 08:05AM	TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors (ACCESSWIRE) +12.77%
Mar-10-25 09:00AM	TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference (ACCESS Newswire) -10.05%
Feb-19-25 09:00AM	TuHURA Biosciences, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (ACCESSWIRE) -12.88%
Dec-12-24 08:45AM	TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. (ACCESSWIRE) -7.88%
Nov-25-24 08:35AM	TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update (ACCESSWIRE) -10.64%
Oct-23-24 08:30AM	TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (ACCESSWIRE)
Oct-22-24 09:00AM	TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor 'New to the Street' Event (ACCESSWIRE) -5.01%
Oct-17-24 04:35PM	TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics (ACCESSWIRE) -6.31% -16.43%
Oct-16-24 12:54PM	Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 (PR Newswire)
11:58AM	Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences (PR Newswire)
04:15PM	Loading…
Oct-15-24 04:15PM	Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 (PR Newswire) +14.70%
Oct-14-24 08:30AM	Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 (PR Newswire) +11.30%
Oct-09-24 07:28AM	Kintara Therapeutics Reveals Improved Financials, Merger Plans (TipRanks)
Oct-08-24 07:00AM	Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update (PR Newswire)
Sep-20-24 09:25AM	Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 (PR Newswire)
Sep-18-24 08:30AM	Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences (PR Newswire) -8.42%
Sep-11-24 08:30AM	Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study (PR Newswire)
Sep-09-24 08:30AM	Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. (PR Newswire)
Aug-19-24 09:00AM	TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer (PR Newswire) +8.16%
Jul-08-24 06:30AM	TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor (PR Newswire) -6.83%
Jul-01-24 08:35AM	Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones (PR Newswire) +10.14%
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -10.11%
Jun-03-24 08:35AM	TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) (PR Newswire) -12.66%
May-30-24 07:47AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +16.54%
May-20-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +22.38%
10:53PM	Loading…
May-14-24 10:53PM	KTRA Stock Earnings: Kintara Therapeutics Reported Results for Q3 2024 (InvestorPlace) -7.25%
04:45PM	Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results (PR Newswire)
Apr-04-24 10:38AM	Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA (Zacks) -12.38%
Apr-03-24 09:46AM	Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today? (InvestorPlace) +63.35%
07:00AM	Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement (PR Newswire)
Mar-27-24 09:00AM	Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab (PR Newswire)
Feb-14-24 04:07PM	Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update (PR Newswire)
Feb-12-24 09:00AM	Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer (PR Newswire) -5.22%
Dec-07-23 09:00AM	Kintara Therapeutics Announces Review of Strategic Alternatives (PR Newswire) -6.85%
Dec-05-23 09:00AM	Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement (PR Newswire) -10.66%
Nov-13-23 04:10PM	Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update (PR Newswire)
Oct-31-23 08:00AM	Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study (PR Newswire) -79.68%
Oct-11-23 08:00AM	Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference (PR Newswire) +8.81%
Oct-02-23 08:00AM	Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference (PR Newswire)
Sep-25-23 07:30AM	Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting (PR Newswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-18-23 04:25PM	Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update (PR Newswire) -11.54% +8.97%
Sep-05-23 08:00AM	Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting (PR Newswire)
Aug-17-23 05:00PM	Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023 (PR Newswire)
Aug-09-23 08:16AM	Kintara Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Aug-08-23 07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Jul-19-23 08:00AM	Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C. (PR Newswire)
Jun-30-23 11:07AM	Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy (Zacks)
Jun-28-23 04:15PM	Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001 (PR Newswire) +40.80%
Jun-16-23 08:00AM	Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference (PR Newswire)
May-19-23 08:30AM	Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society (PR Newswire)
May-11-23 08:15AM	Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update (PR Newswire) -6.74%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 08:30AM	Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference (PR Newswire) -5.04%
May-01-23 08:30AM	Kintara Therapeutics to Present at the Aegis Capital Virtual Conference (PR Newswire)
Apr-14-23 12:00PM	Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting (PR Newswire)
Mar-15-23 08:00AM	Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting (PR Newswire) +17.08%
Mar-10-23 08:30AM	Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023 (PR Newswire) -12.61%
Feb-14-23 05:00PM	Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update (PR Newswire)
Jan-30-23 08:00AM	Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference (PR Newswire) -8.00%
Jan-09-23 08:30AM	Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023 (PR Newswire)
Dec-15-22 08:00AM	Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) (PR Newswire) +14.98%
Dec-02-22 09:47AM	10 Pump and Dump Stocks Hedge Funds Like (Insider Monkey) -13.09%
Dec-01-22 08:00AM	Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 (PR Newswire) +32.24%
Nov-30-22 08:00AM	Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) +12.61%
Nov-28-22 08:00AM	Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer (PR Newswire) +18.24%
Nov-18-22 08:00AM	Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting (PR Newswire)
Nov-11-22 08:00AM	Kintara Announces One-for-Fifty Reverse Stock Split (PR Newswire) -19.21%
Nov-09-22 05:20PM	Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update (PR Newswire) -5.02% +14.65%
Oct-19-22 08:15AM	Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study (PR Newswire) +20.58%
Sep-27-22 08:15AM	Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update (PR Newswire) -19.50%
Sep-08-22 07:00AM	Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting (PR Newswire)
Aug-09-22 09:00AM	Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer (PR Newswire) -9.50%
Aug-03-22 08:30AM	Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital (PR Newswire) +38.26%
Jun-21-22 08:00AM	Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference (PR Newswire) +18.75%
Jun-15-22 09:00AM	Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma (PR Newswire) +25.11%
Jun-10-22 09:00AM	Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference (PR Newswire)
Jun-03-22 09:00AM	Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement (PR Newswire)
May-27-22 09:30AM	Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma (PR Newswire)
May-17-22 07:00AM	7 Penny Stocks With 10x Potential This Year (InvestorPlace)
May-13-22 08:00AM	Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update (PR Newswire) +11.37%
Apr-27-22 09:00AM	Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -16.55%
Apr-26-22 07:30AM	Kintara Therapeutics to Present at the Planet MicroCap Showcase 2022 (PR Newswire) +14.69%
Apr-14-22 04:05PM	Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire) -9.75%
Apr-12-22 11:47AM	Here's Why Kintara Therapeutics (NASDAQ:KTRA) Must Use Its Cash Wisely (Simply Wall St.) -30.71%
08:30AM	Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Apr-11-22 02:30PM	Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting (PR Newswire) +35.41%
Mar-22-22 08:00AM	Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference (PR Newswire)
Mar-15-22 07:00AM	Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting (PR Newswire)
Feb-14-22 06:10AM	KTRA: A Farewell to GBM (Zacks Small Cap Research)
Feb-11-22 08:15AM	Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update (PR Newswire)
Feb-04-22 07:00AM	Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022 (PR Newswire)
Feb-03-22 07:00AM	Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 and MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells (PR Newswire)
Jan-25-22 07:45AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +7.51%
Jan-12-22 08:00AM	Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma (PR Newswire)

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm's lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HURA

TuHURA Biosciences Inc

Upgrade your FINVIZ experience